Know what changed in recruiting studies for a target
The pilot is designed for research and competitive-intelligence work: a dated list of matching studies, traceable NCT identifiers, registry-field matches and a concise explanation of additions, removals and material record changes.
Traceable
Every item links back to its ClinicalTrials.gov record.
Reproducible
The query, retrieval date and versioned snapshot are retained.
Bounded
Registry mentions are not presented as efficacy, endorsement or clinical advice.
Example output · EGFR
Recently updated matching records
Baseline established 2026-09-13. A second snapshot is required before additions and removals can be claimed; the records below are ordered by registry update date.
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
RECRUITING · Memorial Sloan Kettering Cancer Center · PHASE2
Matched fields: title, summary or description, conditions or keywords, eligibility
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
RECRUITING · AstraZeneca
Matched fields: ClinicalTrials.gov search index (match not present in exported fields)
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
RECRUITING · Gruppo Oncologico del Nord-Ovest · PHASE2
Matched fields: summary or description, interventions or arms, eligibility
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
RECRUITING · M.D. Anderson Cancer Center · PHASE1
Matched fields: title, summary or description, eligibility
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
RECRUITING · BeOne Medicines · PHASE1
Matched fields: title, conditions or keywords
Research exports
Pricing experiment — no checkout
Pilot formats under consideration
The initial hypothesis is £99 for a one-off target brief. Approximately £199/month would be tested only if professionals request repeated monitoring. These are exploratory prices, not established market value, and GeneAnalyses is not currently taking payment.
Register interest through the GeneAnalyses publication